EASL update guidelines for treatment of hepatitis C (2013)
1 February 2014. Related: Hepatitis coinfection.
Important notes: EASL further updated these guidelines in April 2014 to include DAAs including sofosbuvir, simeprevir and declatasvir.
http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf (PDF)
The marketing authorisation for simeprevir has since been withdrawn by Janssen (on 1 May 2018) so this drug is no longer available in the EU.
…………………….
In December 2013, the European Association for the Study of the Liver issued revised clinical guidelines for management of hepatitis C. [1]
These Clinical Practice Guidelines (CPGs) are intended to assist physicians and other healthcare providers, as well as patients and other interested individuals, and replace the previous edition in 2011.
Comment
The guidelines note that the document only relates to use of treatment that were approved in Europe in November 2013.
A significant limitation is that the only two direct acting antivirals (DAAs) mentioned in the context of treatment are boceprevir and telaprevir.
In this crucial aspect the guidelines are already out of date and the urgency for addressing this should be a priority for EASL.
Reference:
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol (2014) 60(2);392–420. (February 2104).
http://dx.doi.org/10.1016/j.jhep.2013.11.003 - http://www.journal-of-hepatology.eu/article/S0168-8278(13)00794-0/fulltext
or
http://www.easl.eu/assets/application/files/bdb06ff135c7ccb_file.pdf (PDF download)
Try also:
http://ac.els-cdn.com/S0168827813007940/1-s2.0-S0168827813007940-main.pdf?_tid=e9aaf9e0-94a8-11e3-947c-00000aacb361&acdnat=1392294074_e3cdcb0da5ac14cdbee014e5e2f59ad4